The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.

Fecha de publicación: 01/01/2020 Fecha Ahead of Print: 23/03/2020

Autores de INCLIVA

Valentina Gambardella

Autor
Josefa Castillo Aliaga

Autor
Noelia Tarazona Llavero

Autor
Francisco Gimeno Valiente

Autor
María Carolina Martínez Ciarpaglini

Autor
Manuel Cabeza Segura

Autor
Susana Roselló Keränen

Autor
Desamparados Roda Perez

Autor
María Del Sol Huerta Álvaro

Autor
Andrés Cervantes Ruiperez

Autor
Tania Carolina Fleitas Kanonnikoff

Autor

Grupos y Plataformas de I+D+i

Abstract

Gastric cancer (GC) represents the fifth cause of cancer-related death worldwide. Molecular biology has become a central area of research in GC and there are currently at least three major classifications available to elucidate the mechanisms that drive GC oncogenesis. Further, tumor microenvironment seems to play a crucial role, and tumor-associated macrophages (TAMs) are emerging as key players in GC development. TAMs are cells derived from circulating chemokine- receptor-type 2 (CCR2) inflammatory monocytes in blood and can be divided into two main types, M1 and M2 TAMs. M2 TAMs play an important role in tumor progression, promoting a pro-angiogenic and immunosuppressive signal in the tumor. The diffuse GC subtype, in particular, seems to be strongly characterized by an immuno-suppressive and pro-angiogenic phenotype. No molecular targets in this subgroup have yet been identified. There is an urgent need to understand the molecular pathways and tumor microenvironment features in the GC molecular subtypes. The role of anti-angiogenics and checkpoint inhibitors has recently been clinically validated in GC. Both ramucirumab, a fully humanized IgG1 monoclonal anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody, and checkpoint inhibitors in Epstein Bar Virus (EBV) and Microsatellite Instable (MSI) subtypes, have proved beneficial in advanced GC. Nevertheless, there is a need to identify predictive markers of response to anti-angiogenics and immunotherapy in clinical practice for a personalized treatment approach. The importance of M2 TAMs in development of solid tumors is currently gaining increasing interest. In this literature review we analyze immune microenvironment composition and signaling related to M1 and M2 TAMs in GC as well as its potential role as a therapeutic target. Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Datos de la publicación

ISSN/ISSNe:: 0305-7372, 1532-1967
Tipo:: Article
Páginas:: 102015-102015
DOI:: 10.1016/j.ctrv.2020.102015
PubMed:: 32248000

Documentos

Published Version

Métricas

Filiaciones

Gambardella, V:: CIBER. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain

Instituto de Investigación. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain
Castillo, J:: Universidad. Department of Biochemistry and Molecular Biology, University of Valencia, Valencia, Spain
Tarazona, N:: CIBER. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain

Instituto de Investigación. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain
Gimeno-Valiente, F:: Instituto de Investigación. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain
Martinez-Ciarpaglini, C:: CIBER. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain. Department of Pathology, INCLIVA Biomedical Research Institute, Spain

Instituto de Investigación. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain. Department of Pathology, INCLIVA Biomedical Research Institute, Spain
Cabeza-Segura, M:: Instituto de Investigación. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain
Rosello, S:: CIBER. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain

Instituto de Investigación. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain
Roda, D:: CIBER. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain

Instituto de Investigación. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain
Huerta, M:: Instituto de Investigación. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain
Cervantes, A:: CIBER. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain

Instituto de Investigación. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain
Fleitas, T:: CIBER. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain. Department of Pathology, INCLIVA Biomedical Research Institute, Spain

Instituto de Investigación. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain. Department of Pathology, INCLIVA Biomedical Research Institute, Spain